CRISPR Therapeutics AG (0VRQ.L)
| Previous close | 52.28 |
| Open | 54.09 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 51.15 - 54.52 |
| 52-week range | 37.58 - 91.00 |
| Volume | |
| Avg. volume | 6,308 |
| Market cap | 27.883M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m. ET. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of th
- GlobeNewswire
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively- -Expands pipeline with new preclinical programs utilizing lipid nanopar
- Globe Newswire
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline with new pre-clinical programs utilizing LNP mediated delivery to the liver for refractory hypertension targeting angiotensinogen (AGT) and acute hepatic porphyria (AHP) targeting 5’-aminolevulinate synthase 1 (ALAS1) - - CTX340™, targeting AGT in the liver, achieved durable editing of AGT and sust
